Cmp Development Patent-Cliff Exposure & CMS Drug Spending Portfolio

Cmp Development (US): 5 reconciled FDA prescription therapies, $14.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies5
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2036-01-01
2024 CMS Total Public Spend$14.7M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$12.7M
California HCAI SB 17 Filings2 WAC filings (max 38.2% 2-yr change)